Stocks ETFs & Funds Bonds & Rates Commodities Cryptocurrency Forex Earnings U.S. Tech China Fed Economy Inflation Bitcoin (BTC) Nasdaq 100 Business Energy Wall Street Dividend NYSE Tesla (TSLA) Apple (AAPL) U.K. SEC IPOs Gold NVIDIA (NVDA) Money S&P 500 Ethereum (ETH) Europe Japan Blockchain EUR USD Amazon (AMZN) Ripple (XRP) Investing Dow Jones Microsoft (MSFT) Taxes Meta Platforms (META) GBP USD Retirement Walt Disney (DIS) Health Natural Gas Elon Musk Cars Google Binance Finance Australia Stablecoins Ford Motor (F) Goldman Sachs (GS) Options Coinbase USD JPY Crude Oil Real Estate AUD USD Asia Morgan Stanley (MS) XAU USD Banking Canada NFT REITs Wealth Manufacturing Twitter (TWTR) Mining Coronavirus Netflix (NFLX) USD CAD Insurance JPMorgan (JPM) Silver Dollar Index PayPal (PYPL) Economics Solana (SOL) NZD USD DeFi FOMC Germany Loans Intel (INTC) Environment Walmart (WMT) Bank of America (BAC) Polygon (MATIC) Wells Fargo&Co (WFC) Shiba Inu (SHIB) EUR GBP Steel Alibaba (BABA) AT&T (T) WTI EUR JPY Dogecoin (DOGE) Boeing (BA) France Donald Trump USD CHF BlackRock (BLK)More +
Stock Market News

BioMarin: More Growth Is Coming

Seeking Alpha
Biomarin Pharma (BMRN)
2 months

Are Gene Therapy Stocks The Market’s Next Big Winners?

MarketBeat
24 hours
BioMarin’s share prices fluctuate following Phase 3 clinical trial results

BioMarin’s share prices fluctuate following Phase 3 clinical trial results

Investing.com
1 week

BioMarin: Q2 2023 Confirmed My Bullish View

Seeking Alpha
2 months

Biomarin Pharmaceutical, Inc. (BMRN) Q2 2023 Earnings Call Transcript

Seeking Alpha
2 months
Biomarin Pharma earnings beat by $0.31, revenue topped estimates

Biomarin Pharma earnings beat by $0.31, revenue topped estimates

Investing.com
2 months
Read more news +

© 2023 The Stock Market News